Literature DB >> 17453540

Initial experience with the Amplatzer membranous septal occluder in adults.

Rafael Hirsch1, Avraham Lorber, Yaron Shapira, David Brosh, Asaad Khoury, John L Bass, Ran Kornowski, Alexander Battler.   

Abstract

OBJECTIVES: Most perimembranous ventricular septal defects (pmVSD) that are still patent in adult life are small, hemodynamically and clinically unimportant, and do not require any intervention. However, surgery in adulthood for those that need to be closed carries significant morbidity. A trans-catheter technique for closing pmVSDs has been developed, and this paper describes our initial experience using the Amplatzer membranous septal occluder (AMSO). PATIENTS/
METHODS: Twelve patients, 9 female and 3 male, median age 34.5 years (range: 21-67) underwent catheterization for attempted pmVSD closure. Ten of the defects were native and 2 were post-operative residual defects. Transcatheter VSD closure was performed as previously described, under general anesthesia and with trans-esophageal echocardiographic (TEE) monitoring. Patients had a moderate to large left to right shunt (mean Qp/Qs = 2.0+/-0.4) with mild left heart volume overload and near normal pulmonary pressure. All 10 native pmVSDs were closed successfully, 9 with AMSO and one with an Amplatzer muscular VSD occluder, after failure to implant the AMSO. There was one post procedural complication--self-limiting retroperitoneal bleeding. Three patients had a residual leak. Attempted VSD closure in the 2 patients with post surgery residual shunt was unsuccessful.
CONCLUSION: We conclude that transcatheter mVSD closure with the AMSO is an efficient and safe alternative to surgery in carefully selected adult patients with native pmVSDs.

Entities:  

Mesh:

Year:  2007        PMID: 17453540     DOI: 10.1080/17482940600996894

Source DB:  PubMed          Journal:  Acute Card Care        ISSN: 1748-2941


  1 in total

1.  Transcatheter closure of multi-hole perimembranous VSD with aneurysm: 3-year follow-up study.

Authors:  Hong Wu; Yongwen Qin; Xianxian Zhao; Jianqiang Hu; Xing Zheng; Ersong Wang; Weiping Li; Yanyan Wang; Bo Liu; Jing Liu; Shengqiang Wang
Journal:  Clin Res Cardiol       Date:  2009-07-10       Impact factor: 5.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.